Research Guide: Retatrutide

The Triple Threat

Retatrutide is a "tri-agonist" targeting three distinct receptors:

• GLP-1: Appetite suppression.
• GIP: Metabolic synergy.
• Glucagon (GCG): This is the new addition. While Glucagon normally raises blood sugar, activating its receptor in this specific way increases Energy Expenditure (burning calories) and lipid metabolism.

Essentially: It crushes hunger (GLP-1/GIP) AND turns up the metabolic furnace (GCG).

Pharmacokinetics

Half-Life: Approximately 6 days (~144 hours).

Designed for weekly administration.

Typical Research Titration

Protocols often start lower than Tirzepatide due to the high potency of the Glucagon component (which can increase heart rate in some subjects).

• Start: 2.0mg / week
• Step up: 4.0mg / week
• Step up: 6.0mg - 9.0mg / week
• Max: 12.0mg / week

Caution: Monitor resting heart rate closely during Retatrutide research due to the Glucagon mechanism.